The Full Wiki

More info on Eculizumab

Eculizumab: Wikis

Advertisements
  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Eculizumab ?
Monoclonal antibody
Type whole antibody
Source humanized (from mouse)
Target Complement protein C5
Identifiers
CAS number 219685-50-4
ATC code L04AA25
Chemical data
Formula  ?
Mol. mass 148 kDa
Pharmacokinetic data
Half life 8 to 15 days (mean 11 days)
Therapeutic considerations
Licence data

EU EMEA:linkUS FDA:link

Pregnancy cat. C(US)
Legal status POM (UK) -only (US)
Routes Intravenous infusion

Eculizumab (INN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria.[1]

Eculizumab exhibits its therapeutic activity by binding to the C5 complement protein, thereby blocking its cleavage by the C5 convertase.

Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007 and was later approved by the European Medicines Agency on June 20, 2007.

According to Forbes magazine, Soliris, at $409,500 a year, is the world's single most expensive drug.[2]

References

  1. ^ Hillmen P, Young N, Schubert J, Brodsky R, Socié G, Muus P, Röth A, Szer J, Elebute M, Nakamura R, Browne P, Risitano A, Hill A, Schrezenmeier H, Fu C, Maciejewski J, Rollins S, Mojcik C, Rother R, Luzzatto L (2006). "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria". N Engl J Med 355 (12): 1233–43. doi:10.1056/NEJMoa061648. PMID 16990386. 
  2. ^ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010

External links

Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message